Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial

摘要: Objectives This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated warfarin rivaroxaban. Background There are limited data on AF factor Xa inhibitors. Methods We compared incidence of electrical (ECV), pharmacologic (PCV), and subsequent a post hoc analysis ROCKET (Efficacy Safety Study Rivaroxaban With Warfarin for Prevention Stroke Non-Central Nervous System Systemic Embolism Patients Non-Valvular Atrial Fibrillation) trial. Results Over median follow-up 2.1 years, 143 underwent ECV, 142 PCV, 79 ablation. The overall was 1.45 per 100 patient-years (n = 321; 1.44 [n 161] arm, 1.46 160] rivaroxaban arm). crude rates stroke death increased first 30 days after After adjustment baseline differences, long-term systemic embolism (hazard ratio [HR]: 1.38; 95% confidence interval [CI]: 0.61 3.11), cardiovascular (HR: 1.57; CI: 0.69 3.55), from all causes 1.75; 0.90 3.42) were not different before Hospitalization 2.01; 1.51 2.68), but there no evidence differential effect by randomized treatment (p value interaction 0.58). (1.88% vs. 1.86%) 3.73%) similar rivaroxaban-treated warfarin-treated groups. Conclusions Despite an increase hospitalization, differences survival Outcomes warfarin. (An Efficacy Fibrillation [ROCKET AF]; NCT00403767).